Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksReneuron Share News (RENE)

  • This share is currently suspended. It was suspended at a price of 3.275

Share Price Information for Reneuron (RENE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.275
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 3.275
RENE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET MIDDAY: Wall Street To Follow Europe And China Gains

Fri, 10th Jul 2015 11:07

LONDON (Alliance News) - UK shares are higher Friday midday as Wall Street is expected to take a positive lead from European stocks, boosted by optimism for a deal between Greece and its creditors, and another positive session for Chinese stock markets.

The FTSE 100 index is up 1.3% at 6,667.00, with only three stocks in the red. The FTSE 250 is up 0.9% at 17,448.15, and the AIM All-Share is up 0.4% at 747.45.

European stocks are once again outperforming London, with the CAC 40 in Paris up 2.9% and the DAX 30 in Frankfurt up 2.1%.

Meanwhile, US futures point to a higher open, with the Dow Jones Industrial Average pointed up 1.0%, the S&P 500 up 1.1% and the Nasdaq 100 up 1.2%.

The most important event in the US will be later in the afternoon, as US Federal Reserve Chair Janet Yellen is due to speak about the economic outlook in Cleveland, Ohio, at 1730 BST. Before that, US wholesale inventories are expected 1500 BST.

"With tensions high over the possible approval of a Greek bailout over the weekend, Yellen will probably try not to signal any change to her economic outlook," says CMC Markets analyst Jasper Lawler. "She will receive questions though, so there is some scope for something unexpected."

Outside the US, attention is on Greece. In a move seen as the Mediterranean country's final bid to keep the euro, the government placed a cash-for-reforms proposal before creditors late Thursday. It comprises spending cuts and tax hikes in exchange for a third bailout, acceptance of which will pave the way for further negotiations between both sides.

Eurogroup President Jeroen Dijsselbloem received the proposal from Greece, his spokesman Michel Reijns said in a Twitter message. Eurozone finance ministers will meet on Saturday in Brussels to review the Greek request.

That was meant to be followed by a summit attended by 28 national leaders of the EU on Sunday to reach a final agreement. However an EU official said Friday morning that no EU summit will be held on Sunday if the Eurogroup of finance ministers agrees with the Greek offer on Saturday.

Prime Minister Alexis Tsipras' request for at least EUR53.5 billion in bailout funds for the next three years will be presented in the Greek parliament for approval on Friday. The new list of reforms makes concessions to creditors' demands in key areas including VAT and pension reform, according to a copy of the document seen by dpa.

The Greek program is "serious, credible" and shows "a determination to remain in the euro area", French President Francois Hollande said in a message on Twitter. Nothing is decided yet, everything can be done, he added.

However, IG Markets analyst Alastair McCaig says "there still remains the tricky issue of the Greek parliament approving this proposal, which was by and large rejected in a national referendum less than a week ago," he writes. "Assuming that the Greeks can all agree with themselves we would then need to see the creditors approve this proposal over the weekend. Of course the more cynical market observer will be asking themselves how reliable a Greek promise is anyway."

London and European stocks also are being supported by a second consecutive session of strong gains by Chinese stock markets following successive declines. The Hang Seng closed up 2.1% in Hong Kong and the Shanghai Composite rose 4.5%.

The gains came as China's securities regulator banned senior management and investors who own stakes in businesses exceeding 5% from selling their shares for next six months, and China's central bank injected CNY35 billion into the money market by buying bonds.

The recovery in Chinese equities also lifted metal prices, after they had fallen to multi-year lows earlier in the week.

"This quick recovery [in metal prices] supports our view of fundamentals having taken a backseat as markets were predominantly driven by concerns about Chinese growth and uncertainties related to the equity market correction," says Carsten Menke, commodities research analyst at Julius Baer.

"It remains to be seen whether the Chinese economy will escape unscathed from the equity market correction or whether it will weigh on consumption, e.g. purchases of jewellery and cars," the analyst adds.

The recovery has supported shares in London-listed miners, with BHP Billiton up 2.0%, Glencore up 1.2% and Anglo American up 1.0%.

Elsewhere on the corporate front, InterContinental Hotels Group is up 3.0% after it has agreed to sell its stake in the InterContinental Hong Kong to Supreme Key for USD938 million. Nomura says the value is at the top end of the broker's appraised value of USD783-940 million, and Numis says this looks like a "very acceptable price" and the achieved price is some USD150 million above its expectation.

IHG will retain a 37-year management contract for the hotel, with three ten-year extension rights. It expects to be paid management fees of around USD8 million a year, which will increase after the refurbishment is completed.

International Consolidated Airlines Group is up 2.6%, after Irish budget carrier Ryanair Holdings said its board has voted unanimously to accept IAG's offer for its stake in Aer Lingus Group, removing the final barrier in the way of IAG's takeover bid and paving the way for the protracted transaction to go through. Ryanair shares trade up 2.7%, and Aer Lingus is up 2.4%.

In the AIM All-Share, Aurasian Minerals shares are up 18%. The South-East Asian focused miner said it has appointed Peter Mullens as its new chief executive, and that Mullens has agreed to subscribe to new Aurasian shares alongside a new non-executive director to raise GBP207,500 for the company. The company said Mullens has over 30 years of experience in mining and exploration geology and is currently a director of Royal Road Minerals, which is listed on the Toronto Stock Exchange. Previously, he had held roles at Lydian International and Aquiline Resources.

Reneuron Group is up 16% at 5.66p. The stem-cell company posted a widened pretax loss for its 2015 financial year due to rises in research and development and administrative costs, but said it has placed 1.37 billion shares at 5 pence per share to raise GBP68.4 million to back its therapeutic programmes. Shares in the company closed at 4.875 pence on Thursday.

By Daniel Ruiz; danielruiz@alliancenews.com

Copyright 2015 Alliance News Limited. All Rights Reserved.

More News
23 Nov 2021 16:02

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
19 Nov 2021 12:20

TRADING UPDATES: Symphony Environmental's India foray; Panthera drills

TRADING UPDATES: Symphony Environmental's India foray; Panthera drills

Read more
26 Oct 2021 19:06

TRADING UPDATES: Yellow Cake fundraises; Mercia Asset invests

TRADING UPDATES: Yellow Cake fundraises; Mercia Asset invests

Read more
26 Oct 2021 14:02

ReNeuron enters cancer therapy collaboration with UCL

(Sharecast News) - Cell-based therapeutic specialist ReNeuron has entered a collaboration agreement with University College London (UCL), it announced on Tuesday, to conduct research into the generation of immune cells from induced pluripotent stem cells (iPSCs), for anti-cancer cell therapies.

Read more
21 Oct 2021 16:40

Director dealings: Reneuron Group non-executive makes share purchase

(Sharecast News) - Reneuron Group revealed on Thursday that non-executive director Barbara Staehelin had acquired 43,000 ordinary shares in the AIM-listed cell-based therapeutics developer.

Read more
21 Oct 2021 14:07

DIRECTOR DEALINGS: Inspiration Healthcare exec sells 135,000 shares

DIRECTOR DEALINGS: Inspiration Healthcare exec sells 135,000 shares

Read more
18 Oct 2021 15:12

TRADING UPDATES: Mind Gym revenue recovers; Dispersion buys Accru

TRADING UPDATES: Mind Gym revenue recovers; Dispersion buys Accru

Read more
18 Oct 2021 09:14

ReNeuron treats first Oxford patient as part of expanded study

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group said on Monday that the first UK subject had been treated at the Oxford Eye Hospital as part of its phase 2a clinical evaluations for the treatment of retinitis pigmentosa (RP) - an inherited, degenerative eye disease.

Read more
11 Oct 2021 11:51

ReNeuron upbeat on positive data from Spain collaboration

(Sharecast News) - Exosome therapeutics developer ReNeuron announced positive data on Monday that it said provided "clear preclinical proof-of-concept" that its novel exosome drug delivery technology could effectively deliver therapeutic proteins to the specific region of the brain affected by several neurological diseases.

Read more
11 Oct 2021 11:05

IN BRIEF: ReNeuron gets positive results from exosome drug data

IN BRIEF: ReNeuron gets positive results from exosome drug data

Read more
11 Oct 2021 10:59

AIM WINNERS & LOSERS: Cadence rises on Amapa "landmark"; ASOS dives

AIM WINNERS & LOSERS: Cadence rises on Amapa "landmark"; ASOS dives

Read more
1 Oct 2021 11:15

TRADING UPDATES: Sensyne revenue jumps; Stranger Holdings loss narrows

TRADING UPDATES: Sensyne revenue jumps; Stranger Holdings loss narrows

Read more
1 Oct 2021 10:33

ReNeuron gets approval to restart RP clinical study

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group updated the market on its phase 2a clinical evaluations for the treatment of the inherited, degenerative eye disease retinitis pigmentosa on Friday, confirming that it had received regulatory approval to restart the study in all geographies.

Read more
9 Sep 2021 16:01

UK shareholder meetings calendar - next 7 days

UK shareholder meetings calendar - next 7 days

Read more
6 Aug 2021 10:55

ReNeuron taps Oxford Biomedica executive Catherine Isted as CFO

ReNeuron taps Oxford Biomedica executive Catherine Isted as CFO

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.